Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2004-11-12
2010-06-01
Pryor, Alton N (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
active
07728133
ABSTRACT:
Pharmaceutical compounds having the general formula:or compounds having the formula:where R1and R2are independently H, branched or straight chain alkyl having from 1 to about 7 carbon atoms, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylcycloalkyl, lower alkenyl or R1and R2together form part of a substituted or unsubstituted cycloalkyl having from about 4 of about 7 carbon atoms; where R3is a branched or straight chain alkyl having from 1 to about 7 carbon atoms, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, aralkyl, substituted or unsubstituted alkylcycloalkyl or a group having the formula (CH2)nCOOH where n is from 1 to about 7.
REFERENCES:
patent: 2484029 (1949-10-01), Hartman et al.
patent: 3840639 (1974-10-01), Ueno et al.
patent: 3978057 (1976-08-01), Anderson et al.
patent: 4002753 (1977-01-01), Carpi et al.
patent: 4061636 (1977-12-01), Wise et al.
patent: 4478837 (1984-10-01), Schenker
patent: 4757142 (1988-07-01), Pinza et al.
patent: 6821974 (2004-11-01), Barbeau
patent: 6825196 (2004-11-01), Barbeau
Reece et al, Selective HPLC assays for hydralazine, J. Chromat., 181, pp. 427-440, 1980.
Lacagnin et al, Separation and quantitation of hydralazine metabolites by HPLC, Biochem. Pharmacology, 377, pp. 319-327, 1986.
Druey et al, Hypotensive hydrazinophthalazines and related compounds, J. Medicinal and Pharmaceutical Chemistry, 1959, vol. 1 No. 1, pp. 1-21.
Joshi et al. (Studies on 4-thiozolidinones—synthesis and pharmacological activity for 1,4-bis[2′-methyl /ethyl/phenyl-subsituted styryl-5′H/methyl/carboxymethyl-4′-thiazolidinon-3′-ylamino]phthalazines, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 2000, 39B (12), 967-970). ABS.
Upadhyay et al. (Some new b-lactams and their pharmacological activity, J. of Institute of chemists (India), 1999, 71(5), pp. 173-175). ABS.
Gupta et al. (Biscyclopentadienyltitanium/zirconium IVderivatives with Schiff bases derived from 1,4-dihydrazinophthalazine, Synthesis and Reactivity in inorganic and metal-organic chemistry, 1995, 25(7), 1177-89). ABS.
Upadhyay et al. (Potential chemotherapeutic agents, Indian Drugs, 1991, 29(3), 114-6). ABS.
Mandal et al. (Binuclear copper (II) complexes of some sexadentate phthalazine-hydrazone ligands with strong antiferromagnetic exchange, Inorganic Chimica Acta, 1990, 178 (2), 169-78) ABS.
Okur (Template reactions of 1,4-bis-alpha-carboxybenzylidenehydrazinophtalazine with cobalt, nickel, and chromium, J. of the Chemical Society, Dalton Transactions: Inorganic Chemistry, 1972-1999, 1988, 9, 2293-5)-ABS.
Prescott (Thiosemicarbazones and hydrazones of alpha-methylchalone as potential chemotherapeutic agents, International J. of Clinical Pharmacology and Biopharmacy, 1975, 11(4), 332-5)-ABS.
Maeda et al (Effects of vasodilators on the platelet aggregation and PGI2 generation of vessel wall, Ketsueki to Myakkan, 1983, 14 nol 1, 65-69)—ABS.
Haegele et al. (Identification of hydrallazine and hydrallazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity, British J. of Clinical Pharmacology, 1978, 5 No. 6, 489-94)-ABS.
Prescott et al, 1,4-Phthalazinediyldihydrazones as potential chemotherapeutic agents, Antimicrobial Agents and Chemotherapy, 1961-70, 1970, vol. date 1969, 262-7. ABS.
Druery J. and Marxer A., “Hypotensive Hydrazinophthalazines and Related Compounds”, Journal of Medicinal and Pharmaceutical Chemistry 1(1): 1-21 (1959) Johnson Reprint Corporation New York.
Shepherd A. et al., “Hydralazine kinetics after single and repeated oral doses”, Clinical Pharmacology and Therapeutics 28(6): 804-811 (1980).
Ludden T.M. et al., “Hydralazine kinetics in hypertensive patients after intravenous administration”, Clinical Pharmacology and Therapeutics 28(6): 736-742 (1980).
Haegele K.D. et al., “Quantitative Analysis of Hydralazine Pyruvic Acid Hydrazone, The Major Plasma Metabolite of Hydralazine”, Journal of Chromatography, 187: 171-179 (1980).
Clementi, W.A. et al., “Endogenous Generation of Hydralazine from Labile Hydralazine Hydrazones1”, Journal of Pharmacology and Experimental Therapeutics 222(1): 159-165 (1982).
Ogiso T. et al., “Pharmacokinetics of Formation and Excretion of Some Metabolites of Hydralazine and Their Hypotensive Effect in Rats”, Journal of Pharmacology and Experimental Therapeutics 233(2): 485-490 (1985).
Iwaki M. et al., “In Vitro Kinetic Studies of the Reaction of Hydralazine and its Acetone Hydrazone with Pyruvic Acid”, Journal of Pharmaceutical Sciences 77(3): 280-283 (1988).
McLean A. J. et al., “Interaction of Hydralazine and Hydrazone Derivatives with Contractile Mechanisms in Rabbit Aortic Smooth Muscle1”, Journal of Pharmacology and Experimental Therapeutics 205(2): 418-425 (1978).
Haegele, K.D. et al., “Identification of Hydrallazine and Hycirallazine Hydrazone Metabolites in Human Body Fluids and Quantitative In Vitro Comparisons of their Smooth Muscle Relaxant Activity”, British Journal of Clinical Pharmacology 5: 489-494 (1978).
Barron K. et al., “Comparative Evaluation of the in vitro Effects of Hydralazine and Hydralazine Acetonide on Arterial Smooth Muscle”, British Journal of Pharmacology 621: 345-349 (1977).
Israili Z.H. et al., “Metabolism of Hydralazine”, Drug, Metabolism Reviews 6(2): 283-305 (1977).
O'Donnell, J.P. et al., “Kinetic Studies of Hydralazine Reaction with Acetaldehyde”, Journal of Pharmaceutical Sciences 68(10): 1256-1258(1979).
Zimmer, H., et al., “A Major Metabolite of 1-Hydrazinophthalazine”, Arzneim-Forsch 20(10): 1586-1587 (1970).
Talseth, T., Pharmacokinetics and Cardiovascular Effects in Rabbits of a Major Hydralazine Metabolite, the Hydralzine Pyruvic-Acid Hydrazone 211(3): 509-513 (1979).
McLean, A.J. et al., “Study of In Vitro Effects of Hydralazine Metabolites-Comparative Evaluation of Products of Hydroxylation, Hydrolysis and Conjugation”, Archives International Pharmacodynamics 235: 19-25 (1978).
LaCagnin, L.B. et al., “Metabolic Activation of Hydralazine by Rat Liver Microsomes”, Biochemical Pharmacology 36(16): 2667-2672 (1987).
Lessen, T. et al., “Interactions between Drug Substances and Excipients. 1. Fluorescence and HPLC Studies of Triazolophthalazine Derivatives from Hydralazine Hydrochloride and Starch”. Journal of Pharmaceutical Sciences 85(3): 326-329 (1996).
Schneck, D.W. et al., “Plasma levels of free and acid-labile hydralazine: Effects of multiple dosing and of procainamide”, Clinical Pharmacology and Therapeutics 24(6): 714-719 (1978).
Talseth T. et al., “Hypotensive Effect of the Hydralazine-Acetone Hydrazone in Conscious Rabbits: Evidence for Its Back-Conversion to Hydralazine In Vivo”, Journal of Cardiovascular Pharmacology 4: 370-374 (1982).
McLean, A.J. et al., “Comparative Evaluation of the Hypotensive Activity of Two Major Metabolites of Hydralazine (1-Hydrazinophthalazine)” European Journal of Drug Metabolism and Pharmacokinetics 1: 17-20 (1977).
Juchau, M.R. et al., “Metabolism of Hydrazine Derivatives of Pharmacological Interest”, Drug Metabolism Reviews 1(1): 71-100 (1972).
Haegele, K.D. et al., “Determination of Hydralazine and its Metabolites by Gas Chromatography-Mass Spectrometry”, Journal of Chromatography 126: 517-534 (1976).
Ludden et al., “High-Pressure Liquid Chromatographic Assay for Hydralazine in Human Plasma”, Journal of Pharmaceutical Sciences 68(11) 1423-1425 (1979).
O'Donnell, J.P. et al., “High-Performance Liquid Chromatographic Studies of Reaction of Hydralazine with Biogenic Aldehydes and Ketones”, Journal of Pharmaceutical Sciences 68(12) 1524-1526 (1979)
Pryor Alton N
Schiff & Hardin LLP
LandOfFree
Stable pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155090